Lead Product Candidate
Specialty High-Titer Immune Globulin
Our lead product candidate (RI-002) targets the unmet needs of immune deficient patients, of which, a Biologics License Application (BLA) was submitted to the FDA in July 2015. RI-002 demonstrated positive Phase III results and successfully achieved its primary endpoint of preventing serious bacterial infections such as bacterial pneumonia, osteomyelitis and bacterial sepsis in immune compromised PIDD patients.
ADMA Biologics is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Our product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with infectious diseases.
ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified source plasma collection facility which provides a portion of blood plasma for the manufacture of our lead product candidate RI-002.
FDA Approved Plasma Procurement
Plasma Collection Center
Our FDA-licensed, GHA-certified source plasma collection facility provides safe, self-sourced raw material plasma for our lead product candidate as well as serves the needs of our customers with a reliable supply of source plasma. Click here for more information. Learn how to become a life-saving plasma donor today!
- Dec 9, 2015 ADMA Biologics Expands Commercial Operations Team in Preparation for Commercial Launch of RI-002 in Second Half of 2016
- Dec 3, 2015 ADMA Biologics to Present at the Oppenheimer 26th Annual Healthcare Conference
- Nov 10, 2015 ADMA Biologics Reports Third Quarter 2015 Results
- Nov 3, 2015 ADMA Biologics Announces Data to be Presented at the International Primary Immunodeficiencies Congress in Budapest Hungary